ERBB2 and breast cancer: The bystander effect of payloads like DXd enables trastuzumab deruxtecan to effectively target HER2-heterogeneous breast cancers, achieving objective response rates of up to 70% in pretreated HER2-positive disease and over 50% in HER2-low tumors [117].